Domestic medicines to use TKDN materials: Health Ministry

The Health Ministry is ensuring that domestic drug production absorbs a high percentage of Domestic Component Level (TKDN), according to Arianti Anaya,  the ministry;s acting director general of pharmaceuticals and medical devices.

“With the regulations to support TKDN, we are ensuring the domestic drug market will have high TKDN,” Anaya confirmed at the ‘National Forum for the Independence and Resilience of the Pharmaceutical Industry’ on Tuesday.

To encourage an increase in TKDN in domestic pharmaceutical products, the Ministry of Health has also prepared a strategic plan to accelerate the resilience of the national pharmaceutical industry, she said.

The strategic plan targets the production of 10 molecules or medicinal raw materials (BBO), 10 medical devices, and 14 regular vaccines in Indonesia by 2024, she informed.

“Most of them are still imported and we are targeting to have domestic materials in the future,” she explained.

To attract investment for achieving the production target, the government will create regulations to ensure that domestic health products are distributed to users, such as doctors, nurses, and health workers, Anaya said.

“Of course, the domestic industry must be able to produce competitive products, not only for domestic consumption but also for export to foreign countries,” she emphasized.

She said she believes that Indonesia will be able to meet the 2024 strategic plan target since the country has many natural resources that can be processed to make pharmaceutical products.

“We are a country with a lot of natural resources that can be used, both for raw materials in traditional medicines and chemical drugs. There are also biological products that we can develop through collaboration with academics and the National Agency of Drug and Food Control (BPOM). We are committed to developing domestic products,” she added.

 

 

Source: Antara News